Definitive Healthcare Corp.
HealthcareNASDAQ:DH · NASDAQ Global Select
-$0.01 today
Vol 0.16M · Avg 0.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.4%
avg -25.7%
ROIC
-3.3%
avg -13.7%
ROA
-18.9%
avg -10.8%
Analysis
ROIC is currently the strongest return metric at -3.3% versus its period average of -13.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin D. Coop | Chief Executive Officer & Director | $907,397.00 | — | 61 | $5.08M | 4.81% |
Casey Heller | Chief Financial Officer | $522,614.00 | — | 37 | $2.01M | 1.90% |
Jason Ronald Krantz | Founder & Executive Chairman | $61,371.00 | — | 52 | $1.20M | 1.14% |
Jonathan Paris | Chief Legal Officer & Secretary | — | — | 50 | $902,854.00 | 0.86% |
Marissa Peoples Odell | SVP & Head of Sales | — | — | — | — | — |
Rebecca Marani | Senior VP & Head of Product | — | — | — | — | — |
Tina Hannagan | Chief Commercial Officer | — | — | — | — | — |
Jeannine Lombardi Sheehan | Chief Human Resources Officer | — | — | 52 | — | — |
Sally Slarke | Senior Vice President of Commercial Center of Excellence | — | — | — | — | — |
Benjamin Graboske | EVice President, Technology, Engineering & Chief Data Officer | — | — | 55 | $1.31M | 1.24% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +28.6% | -0.8% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +28.6% over three years. Forward estimates point to Revenue at -0.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
National Research Corporation
NASDAQ:NRC
$423.46M
TruBridge, Inc.
NASDAQ:TBRG
$391.78M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$349.74M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Spok Holdings, Inc.
NASDAQ:SPOK
$227.67M
Owens & Minor, Inc.
OMI
$207.07M
Nakamoto Inc.
NASDAQ:NAKA
$75.18M
Who manages DH?
Definitive Healthcare Corp. (DH) lists 10 active executives. The top listed executive is Casey Heller, Chief Financial Officer.
Are DH insiders buying or selling?
Recent insider activity shows net selling of $65.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.